Arixtra’s sales are running at about one-twentieth of Lovenox’s sales (#msg-26740202) Absent new clinical data, how is a generic version of Arixtra going to make any material difference to the market for branded and/or generic Lovenox?
It won’t. This is not even on MNTA’s radar screen.
News 
Market Data 
Discover 
